New Millennium Group’s Capricor Therapeutics CAPR Stock Holding History

New Millennium Group’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$317	Sell	11 -5	-31%	-$65	﹤0.01%	362
2025 Q3	$115	Hold	16	–	–	﹤0.01%	456
2025 Q2	$159	Sell	16 -18	-53%	-$190	﹤0.01%	394
2025 Q1	$323	Sell	34 -25	-42%	-$347	﹤0.01%	436
2024 Q4	$814	Hold	59	–	–	﹤0.01%	472
2024 Q3	$897	Hold	59	–	–	﹤0.01%	338
2024 Q2	$281	Buy	+59	New	+$329	﹤0.01%	387
2024 Q1	–	Sell	-59	Closed	-$289	–	115
2023 Q4	$289	Hold	59	–	–	﹤0.01%	406
2023 Q3	$202	Hold	59	–	–	﹤0.01%	383
2023 Q2	$282	Hold	59	–	–	﹤0.01%	385
2023 Q1	$249	Hold	59	–	–	﹤0.01%	405
2022 Q4	$228	Hold	59	–	–	﹤0.01%	443
2022 Q3	$0	Sell	59 -10	-14%	-$51	﹤0.01%	370
2022 Q2	$0	Buy	+69	New	+$245	﹤0.01%	360

Other funds holding CAPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

New Millennium Group's CAPR Position: Q4 2025 in Review

New Millennium Group reduced its Capricor Therapeutics (CAPR) stake by 31% in Q4 2025, selling an estimated $65 and leaving 11 shares worth $317. The position accounts for ﹤0.01% of the portfolio, ranked #362.

New Millennium Group first reported a position in CAPR in Q2 2022 and has held it in 14 quarters since. The position peaked at $897 in Q3 2024. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

New Millennium Group held 11 shares of Capricor Therapeutics worth $317 as of Q4 2025.
New Millennium Group sold 5 Capricor Therapeutics shares in Q4 2025, an estimated $65.
Capricor Therapeutics made up ﹤0.01% of New Millennium Group's portfolio in Q4 2025, its #362 holding.
New Millennium Group first reported a position in Capricor Therapeutics in Q2 2022 and has held it in 14 quarters since.
New Millennium Group's Capricor Therapeutics position peaked at $897 in Q3 2024.
132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on New Millennium Group's 13F filing for Q4 2025, filed 6 Feb 2026.